Cardiology
RSSArticles
-
Healthcare Personnel COVID-19 Hospitalizations and Vaccine Prioritization
During the period of study, 5.9% of individuals hospitalized for COVID-19-related reasons were healthcare providers (HCP), with approximately one-third involving HCP who were not expected to directly contact patients.
-
Managing Appendicitis Medically
A multicenter, randomized trial showed that 10 days of antibiotics results in comparable outcomes as surgery. Three in 10 patients treated with antibiotics required surgery within 90 days.
-
Patients with Higher Renin Levels May Derive More Benefit from Angiotensin II Treatment
Serum renin concentration in patients with catecholamine-resistant vasodilatory shock may identify those for whom treatment with angiotensin II has improved intensive care unit outcomes.
-
Convalescent Plasma Therapy Does Not Affect Time to Clinical Improvement in Patients with Severe and Life-Threatening COVID-19
This was a randomized, open-label, multicenter trial of intravenous convalescent plasma infusion (4 mL/kg to 13 mL/kg) therapy. Convalescent plasma therapy was not associated with improvements in mortality or time to clinical improvement.
-
A Review of Current Therapeutics for Severe COVID-19 Pneumonia
The aim of this special feature is to review therapeutic options for hospitalized patients with COVID-19 pneumonia.
-
A New Treatment for Refractory Hyperlipidemia
In patients with familial hypercholesterolemia who are not at target LDL cholesterol levels on maximum-tolerated doses of statins and PCSK9 inhibitors, evinacumab, which inhibits angiopoietin-like 3, reduces LDL by more than 50% at the highest doses with few side effects requiring drug discontinuation vs. placebo.
-
Expanding Uses for Direct Oral Anticoagulants: Bioprosthetic Heart Valves?
A randomized, controlled trial of rivaroxaban vs. warfarin in patients with atrial fibrillation and a bioprosthetic valve revealed rivaroxaban is noninferior to warfarin for the prevention of major cardiovascular events and the avoidance of major bleeding events over 12 months.
-
Time is of the Essence with Colchicine Treatment of Myocardial Infarction
An analysis of the COLCOT study of colchicine administration after myocardial infarction (MI) showed the benefit of this therapy for preventing subsequent cardiovascular events was greatest when therapy was initiated within three days after MI onset.
-
Left Ventricular Size, Function Predictors of Outcomes in Chronic Aortic Regurgitation
In a large cohort of asymptomatic patients with hemodynamically significant chronic aortic regurgitation, volumetric left ventricular size and function measurements were equally discriminant in identifying patients at higher risk for mortality vs. traditional linear measurements.
-
What Causes MINOCA?
A systematic imaging protocol of coronary angiography, optical coherence tomography, and cardiac MRI in women clinically diagnosed with myocardial infarction with non-obstructive coronary artery disease revealed a cause in 84%, with three-quarters exhibiting an ischemic etiology.